Recent Updates
Recently added Catalysts
GERN Negative Sentiment Score: 35/100

GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Geron Corporation on behalf of long-term stockholders due to a class action complaint filed on March 14, 2025. The investigation focuses on allegations of breaches of fiduciary duties by Geron's board of directors. The complaint claims that Geron misled investors about the commercial potential of its drug Rytelo (imetelstat) while downplaying significant risks. Stakeholders with information or questions are encouraged to contact the law firm for further guidance.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investigation into Geron Corporation suggests possible breach of fiduciary duties by the board.
  • Class action complaint raises concerns about misleading information provided to investors regarding Rytelo's market potential.
  • Allegations of minimizing risks associated with Rytelo's launch and competition could impact investor confidence.

Full Press Release Details

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. Our investigation concerns whether the board of directors of Geron have breached their fiduciary duties to the company.
The Complaint alleges that throughout the Class Period, Defendants provided investors with material information concerning Defendants' expectations for the launch and growth potential of Rytelo (imetelstat). The Complaint alleges that Defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug's sales.
If you are a long-term stockholder of Geron, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the purpose of Bragar Eagel & Squire's investigation?

The investigation seeks to determine if Geron's board breached fiduciary duties.

What was the Class Period for the Geron lawsuit?

The Class Period runs from February 28, 2024, to February 25, 2025.

What drug is at the center of the Geron lawsuit?

The lawsuit centers around Rytelo (imetelstat) and its market potential.

How can Geron stockholders get more information?

Stockholders can contact Bragar Eagel & Squire via email or phone for details.

Is there a cost for stockholders to inquire about claims?

No, there is no cost or obligation for stockholders to make inquiries.

Last updated: Aug 13, 2025